U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C58H73N7O17
Molecular Weight 1140.2392
Optical Activity UNSPECIFIED
Defined Stereocenters 15 / 15
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ANIDULAFUNGIN

SMILES

CCCCCOc1ccc(cc1)-c2ccc(cc2)-c3ccc(cc3)C(=O)N[C@@]4([H])C[C@]([H])([C@]([H])(N=C([C@]5([H])[C@]([H])([C@@]([H])(C)CN5C(=O)[C@]([H])([C@@]([H])(C)O)N=C([C@]([H])([C@@]([H])([C@]([H])(c6ccc(cc6)O)O)O)N=C([C@]7([H])C[C@]([H])(CN7C(=O)[C@]([H])([C@@]([H])(C)O)N=C4O)O)O)O)O)O)O)O

InChI

InChIKey=JHVAMHSQVVQIOT-MFAJLEFUSA-N
InChI=1S/C58H73N7O17/c1-5-6-7-24-82-40-22-18-35(19-23-40)33-10-8-32(9-11-33)34-12-14-37(15-13-34)51(74)59-41-26-43(70)54(77)63-56(79)47-48(71)29(2)27-65(47)58(81)45(31(4)67)61-55(78)46(50(73)49(72)36-16-20-38(68)21-17-36)62-53(76)42-25-39(69)28-64(42)57(80)44(30(3)66)60-52(41)75/h8-23,29-31,39,41-50,54,66-73,77H,5-7,24-28H2,1-4H3,(H,59,74)(H,60,75)(H,61,78)(H,62,76)(H,63,79)/t29-,30+,31+,39+,41-,42-,43+,44-,45-,46-,47-,48-,49-,50-,54+/m0/s1

HIDE SMILES / InChI

Molecular Formula C58H73N7O17
Molecular Weight 1140.2392
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 15 / 15
E/Z Centers 0
Optical Activity UNSPECIFIED

Anidulafungin (brand names Eraxis (in U.S. and Russia) and Ecalta (in Europe)) is a semi-synthetic echinocandin with antifungal activity and it is active in vitro against many Candida, as well as some Aspergillus. Like other echinocandins, anidulafungin is not active against Cryptococcus neoformans, Trichosporon, Fusarium, or zygomycetes. This drug is indicated for the treatment of candidemia and the following Candida infections: intra-abdominal abscess and peritonitis; and for the treatment of esophageal candidiasis. Anidulafungin inhibits glucan synthase, an enzyme present in fungal, but not mammalian cells. This results in inhibition of the formation of 1,3--D-glucan, an essential component of the fungal cell wall.

CNS Activity

Curator's Comment:: The ability of the echinocandin, anidulafungin to penetrate the blood-CSF/blood-brain barrier is poor as a consequence of their high molecular mass (above 1,000 Da).

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
ERAXIS

Approved Use

ERAXIS is indicated for use in adults for the treatment of the following fungal infections listed below. Specimens for fungal culture and other relevant laboratory studies (including histopathology) should be obtained prior to therapy to isolate and identify causative organism(s). Therapy may be instituted before the results of the cultures and other laboratory studies known. However, once these results become available, antifungal therapy should be adjusted accordingly. Anidulafungin is an echinocandin antifungal drug indicated in adults for the treatment of: Candidemia and other forms of Candida infections (intra-abdominal abscess and peritonitis) (1.1) Esophageal candidiasis (1.2) Limitations of use: has not been studied in endocarditis, osteomyelitis and meningitis due to Candida or in sufficient numbers of neutropenic patients (1.3) 1.1 Candidemia and Other Forms of Candida Infections (Intra-abdominal Abscess and Peritonitis) ERAXIS is indicated for the treatment of candidemia and the following Candida infections: intra-abdominal abscess and peritonitis [see Clinical Studies(14.1) and Clinical Pharmacology, Microbiology (12.4)

Launch Date

1.14013438E12
Curative
ERAXIS

Approved Use

ERAXIS is indicated for use in adults for the treatment of the following fungal infections listed below. Specimens for fungal culture and other relevant laboratory studies (including histopathology) should be obtained prior to therapy to isolate and identify causative organism(s). Therapy may be instituted before the results of the cultures and other laboratory studies known. However, once these results become available, antifungal therapy should be adjusted accordingly. Anidulafungin is an echinocandin antifungal drug indicated in adults for the treatment of: Candidemia and other forms of Candida infections (intra-abdominal abscess and peritonitis) (1.1) Esophageal candidiasis (1.2) Limitations of use: has not been studied in endocarditis, osteomyelitis and meningitis due to Candida or in sufficient numbers of neutropenic patients (1.3) 1.1 Candidemia and Other Forms of Candida Infections (Intra-abdominal Abscess and Peritonitis) ERAXIS is indicated for the treatment of candidemia and the following Candida infections: intra-abdominal abscess and peritonitis [see Clinical Studies(14.1) and Clinical Pharmacology, Microbiology (12.4)

Launch Date

1.14013438E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
7.2 mg/L
200 mg 1 times / day steady-state, intravenous
dose: 200 mg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
ANIDULAFUNGIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
4.2 mg/L
100 mg 1 times / day steady-state, intravenous
dose: 100 mg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
ANIDULAFUNGIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
110.3 mg × h/L
200 mg 1 times / day steady-state, intravenous
dose: 200 mg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
ANIDULAFUNGIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
55.2 mg × h/L
100 mg 1 times / day steady-state, intravenous
dose: 100 mg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
ANIDULAFUNGIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
26.5 h
200 mg 1 times / day steady-state, intravenous
dose: 200 mg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
ANIDULAFUNGIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
26.5 h
100 mg 1 times / day steady-state, intravenous
dose: 100 mg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
ANIDULAFUNGIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
1%
200 mg 1 times / day steady-state, intravenous
dose: 200 mg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
ANIDULAFUNGIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1%
100 mg 1 times / day steady-state, intravenous
dose: 100 mg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
ANIDULAFUNGIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
200 mg 1 times / day multiple, intravenous
Recommended
Dose: 200 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 200 mg, 1 times / day
Sources: Page: p.4
unhealthy, 16-89
n = 127
Health Status: unhealthy
Condition: Candida infections|Candidemia
Age Group: 16-89
Sex: M+F
Population Size: 127
Sources: Page: p.4
Disc. AE: Multi-organ failure...
AEs leading to
discontinuation/dose reduction:
Multi-organ failure
Sources: Page: p.4
200 mg 1 times / day multiple, intravenous
Recommended
Dose: 200 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 200 mg, 1 times / day
Sources: Page: p.4
unhealthy, 56.5 (± 18.5)
n = 43
Health Status: unhealthy
Condition: Candidemia
Age Group: 56.5 (± 18.5)
Sex: M+F
Population Size: 43
Sources: Page: p.4
Disc. AE: Drug hypersensitivity, Skin rash...
AEs leading to
discontinuation/dose reduction:
Drug hypersensitivity (2.3%)
Skin rash (2.3%)
Sources: Page: p.4
400 mg single, intravenous
Overdose
Dose: 400 mg
Route: intravenous
Route: single
Dose: 400 mg
Sources: Page: p.9
unhealthy
Health Status: unhealthy
Condition: Candida infections|Candidemia
Sources: Page: p.9
200 mg 1 times / day multiple, intravenous
Recommended
Dose: 200 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 200 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Candida infections|Candidemia
Sources: Page: p.1
Disc. AE: Abnormal liver function tests, Hepatitis...
AEs leading to
discontinuation/dose reduction:
Abnormal liver function tests
Hepatitis
Hepatic failure
Hypersensitivity
Anaphylaxis
Rash
Urticaria
Flushing
Pruritus
Bronchospasm
Dyspnea
Hypotension
Sources: Page: p.1
AEs

AEs

AESignificanceDosePopulation
Multi-organ failure Disc. AE
200 mg 1 times / day multiple, intravenous
Recommended
Dose: 200 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 200 mg, 1 times / day
Sources: Page: p.4
unhealthy, 16-89
n = 127
Health Status: unhealthy
Condition: Candida infections|Candidemia
Age Group: 16-89
Sex: M+F
Population Size: 127
Sources: Page: p.4
Drug hypersensitivity 2.3%
Disc. AE
200 mg 1 times / day multiple, intravenous
Recommended
Dose: 200 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 200 mg, 1 times / day
Sources: Page: p.4
unhealthy, 56.5 (± 18.5)
n = 43
Health Status: unhealthy
Condition: Candidemia
Age Group: 56.5 (± 18.5)
Sex: M+F
Population Size: 43
Sources: Page: p.4
Skin rash 2.3%
Disc. AE
200 mg 1 times / day multiple, intravenous
Recommended
Dose: 200 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 200 mg, 1 times / day
Sources: Page: p.4
unhealthy, 56.5 (± 18.5)
n = 43
Health Status: unhealthy
Condition: Candidemia
Age Group: 56.5 (± 18.5)
Sex: M+F
Population Size: 43
Sources: Page: p.4
Abnormal liver function tests Disc. AE
200 mg 1 times / day multiple, intravenous
Recommended
Dose: 200 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 200 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Candida infections|Candidemia
Sources: Page: p.1
Anaphylaxis Disc. AE
200 mg 1 times / day multiple, intravenous
Recommended
Dose: 200 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 200 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Candida infections|Candidemia
Sources: Page: p.1
Bronchospasm Disc. AE
200 mg 1 times / day multiple, intravenous
Recommended
Dose: 200 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 200 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Candida infections|Candidemia
Sources: Page: p.1
Dyspnea Disc. AE
200 mg 1 times / day multiple, intravenous
Recommended
Dose: 200 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 200 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Candida infections|Candidemia
Sources: Page: p.1
Flushing Disc. AE
200 mg 1 times / day multiple, intravenous
Recommended
Dose: 200 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 200 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Candida infections|Candidemia
Sources: Page: p.1
Hepatic failure Disc. AE
200 mg 1 times / day multiple, intravenous
Recommended
Dose: 200 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 200 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Candida infections|Candidemia
Sources: Page: p.1
Hepatitis Disc. AE
200 mg 1 times / day multiple, intravenous
Recommended
Dose: 200 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 200 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Candida infections|Candidemia
Sources: Page: p.1
Hypersensitivity Disc. AE
200 mg 1 times / day multiple, intravenous
Recommended
Dose: 200 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 200 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Candida infections|Candidemia
Sources: Page: p.1
Hypotension Disc. AE
200 mg 1 times / day multiple, intravenous
Recommended
Dose: 200 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 200 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Candida infections|Candidemia
Sources: Page: p.1
Pruritus Disc. AE
200 mg 1 times / day multiple, intravenous
Recommended
Dose: 200 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 200 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Candida infections|Candidemia
Sources: Page: p.1
Rash Disc. AE
200 mg 1 times / day multiple, intravenous
Recommended
Dose: 200 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 200 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Candida infections|Candidemia
Sources: Page: p.1
Urticaria Disc. AE
200 mg 1 times / day multiple, intravenous
Recommended
Dose: 200 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 200 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Candida infections|Candidemia
Sources: Page: p.1
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



OverviewOther

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
inconclusive
no
no
no
no
no (co-administration study)
Comment: rifampin did not significantly alter anidulafungin pharmacokinetics
Page: 44.0
no
no (co-administration study)
Comment: rifampin did not significantly alter anidulafungin pharmacokinetics
Page: 44.0
no
no (co-administration study)
Comment: voriconazole did not significantly alter anidulafungin pharmacokinetics
Page: 44.0
no
no (co-administration study)
Comment: voriconazole did not significantly alter anidulafungin pharmacokinetics; rifampin did not significantly alter anidulafungin pharmacokinetics
Page: 44.0
no
no (co-administration study)
Comment: rifampin did not significantly alter anidulafungin pharmacokinetics
Page: 44.0
no
no (co-administration study)
Comment: cyclosporine did not significantly alter anidulafungin pharmacokinetics; voriconazole did not significantly alter anidulafungin pharmacokinetics; rifampin did not significantly alter anidulafungin pharmacokinetics
Page: 44.0
strong [IC50 7 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
inconclusive
no
no (co-administration study)
Comment: rifampin did not significantly alter anidulafungin pharmacokinetics
Page: 44, 54
PubMed

PubMed

TitleDatePubMed
The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications.
2006
Echinocandin antifungals: review and update.
2006 Apr
Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis.
2006 Apr
Anidulafungin: a new echinocandin for the treatment of fungal infections.
2006 Aug
In vitro interactions of anidulafungin with azole antifungals, amphotericin B and 5-fluorocytosine against Candida species.
2006 Feb
Anidulafungin: a novel echinocandin.
2006 Jul 15
Voriconazole in the management of nosocomial invasive fungal infections.
2006 Jun
Gateways to clinical trials.
2006 May
Emerging echinocandins for treatment of invasive fungal infections.
2006 May
Another option for fungal infections.
2006 May-Jun
New drugs: lubiprostone, ranolazine, and anidulafungin.
2006 May-Jun
Echinocandins in the management of invasive fungal infections, Part 2.
2006 Oct 1
Gateways to clinical trials.
2006 Sep
Echinocandins for candidemia in adults without neutropenia.
2006 Sep 14
Echinocandins in the management of invasive fungal infections, part 1.
2006 Sep 15
Antifungal agents in neonates: issues and recommendations.
2007
Role of micafungin in the antifungal armamentarium.
2007
Anidulafungin--state of affairs from a clinical perspective.
2007
Fungal infections of the CNS: treatment strategies for the immunocompromised patient.
2007
Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairment.
2007 Apr
Role of posaconazole in the management of oropharyngeal and esophageal candidiasis.
2007 Aug
One year prospective survey of Candida bloodstream infections in Scotland.
2007 Aug
[In vitro activity of amphotericin B and anidulafungin against Candida spp. biofilms].
2007 Dec 31
New drugs 07, part I.
2007 Feb
Anidulafungin: a new echinocandin for candidal infections.
2007 Feb
A comparative evaluation of properties and clinical efficacy of the echinocandins.
2007 Jul
Nongastroesophageal reflux disease-related infectious, inflammatory and injurious disorders of the esophagus.
2007 Jul
Development of anidulafungin for disk diffusion susceptibility testing against Candida spp.
2007 Jul
Update on new antifungal therapy.
2007 Jul-Sep
Echinocandins--first-choice or first-line therapy for invasive candidiasis?
2007 Jun 14
Anidulafungin versus fluconazole for invasive candidiasis.
2007 Jun 14
Comparison of echinocandin antifungals.
2007 Mar
Essential gene identification and drug target prioritization in Aspergillus fumigatus.
2007 Mar
Lack of pharmacokinetic interaction between anidulafungin and tacrolimus.
2007 Mar
The echinocandins.
2007 Mar
Antifungal drug discovery, six new molecules patented after 10 years of feast: why do we need new patented drugs apart from new strategies?
2007 Nov
Mould breakthrough in immunosuppressed adults receiving anidulafungin: a report of 2 cases.
2007 Nov
Management of invasive pulmonary aspergillosis in non-neutropenic critically ill patients.
2007 Oct
Recent advances in antifungal agents.
2007 Sep
Susceptibility patterns of Candida species recovered from Canadian intensive care units.
2007 Sep
Anidulafungin and fluconazole for candidiasis.
2007 Sep 27
Bench-to-bedside review: Candida infections in the intensive care unit.
2008
Stimulation of chitin synthesis rescues Candida albicans from echinocandins.
2008 Apr 4
In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates.
2008 Aug
Management of Candida infections in the adult intensive care unit.
2008 Feb
Early clinical experience with anidulafungin at a large tertiary care medical center.
2008 Jan
Propofol lipidic infusion promotes resistance to antifungals by reducing drug input into the fungal cell.
2008 Jan 17
Anidulafungin was noninferior to fluconazole for invasive candidiasis.
2008 Jan-Feb
[Anidulafungin in the invasive fungal infection: current topics].
2008 Jun
Liposomal amphotericin B: what is its role in 2008?
2008 May
Patents

Patents

Sample Use Guides

Candidemia and other Candida infections (intra-abdominal abscess, and peritonitis) The recommended dose is a single 200 mg loading dose on Day 1, followed by 100 mg daily dose thereafter. Duration of treatment should be based on the patient’s clinical response. In general, antifungal therapy should continue for at least 14 days after the last positive culture. Esophageal Candidiasis: The recommended dose is a single 100 mg loading dose on Day 1, followed by 50 mg daily dose thereafter. Patients should be treated for a minimum of 14 days and for at least 7 days following resolution of symptoms. Duration of treatment should be based on the patient’s clinical response. Because of the risk of relapse of esophageal candidiasis in patients with HIV infections, suppressive antifungal therapy may be considered after a course of treatment.
Route of Administration: Intravenous
A 48 hours exposure of human erythrocytes to Anidulafungin (1.5 - 6 µg/ml) significantly increased hemolysis and the percentage of annexin-V-binding cells, and significantly decreased forward scatter. Anidulafungin (6 µg/ml) slightly, but significantly inceased Fluo3-fluorescence and the effect of Anidulafungin on annexin-V-binding was slightly, but significantly blunted by removal of extracellular Ca2+. The effect of Anidulafungin on annexin-V-binding was further significantly blunted by the p38 kinase inhibitor SB203580 (2 µM) and NO donor nitroprusside (1 µM). An increase of extracellular K+ concentration significantly blunted the effect of Anidulafungin on cell volume but not on annexin-V-binding.
Substance Class Chemical
Created
by admin
on Sat Jun 26 10:26:37 UTC 2021
Edited
by admin
on Sat Jun 26 10:26:37 UTC 2021
Record UNII
9HLM53094I
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ANIDULAFUNGIN
EMA EPAR   INN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
VER002
Code English
LY-303366
Code English
ANIDULAFUNGIN [ORANGE BOOK]
Common Name English
D70013
Code English
ANIDULAFUNGIN [VANDF]
Common Name English
LY303366
Code English
ERAXIS
Brand Name English
ANIDULAFUNGIN [WHO-DD]
Common Name English
ANIDULAFUNGIN [USAN]
Common Name English
ECHINOCANDIN B, 1-((4R,5R)-4,5-DIHYDROXY-N(SUP 2)-((4''-(PENTYLOXY)(1,1':4',1''-TERPHENYL)-4-YL)CARBONYL)-L-ORNITHINE)-
Common Name English
V-ECHINOCANDIN
Common Name English
(4R,5R)-4,5-DIHYDROXY-N(SUP 2)-((4''-(PENTYLOXY)-P-TERPHENYL-4-YL)CARBONYL)-L-ORNITHYL-L-THREONYL-TRANS-4-HYDROXY-L-PROLYL-(S)-4-HYDROXY-4-(P-HYDROXYPHENYL)-L-THREONYL-L-THREONYL-(3S,4S)-3-HYDROXY-4-METHYL-L-PROLINE CYCLIC (6->1)-PEPTIDE
Common Name English
VER-002
Code English
ANIDULAFUNGIN [MART.]
Common Name English
ANIDULAFUNGIN [EMA EPAR]
Common Name English
D-70013
Common Name English
ANIDULAFUNGIN [INN]
Common Name English
ANIDULAFUNGIN [MI]
Common Name English
Classification Tree Code System Code
LIVERTOX 58
Created by admin on Sat Jun 26 10:26:38 UTC 2021 , Edited by admin on Sat Jun 26 10:26:38 UTC 2021
NDF-RT N0000175508
Created by admin on Sat Jun 26 10:26:38 UTC 2021 , Edited by admin on Sat Jun 26 10:26:38 UTC 2021
NDF-RT N0000175507
Created by admin on Sat Jun 26 10:26:38 UTC 2021 , Edited by admin on Sat Jun 26 10:26:38 UTC 2021
NCI_THESAURUS C514
Created by admin on Sat Jun 26 10:26:38 UTC 2021 , Edited by admin on Sat Jun 26 10:26:38 UTC 2021
WHO-ATC J02AX06
Created by admin on Sat Jun 26 10:26:38 UTC 2021 , Edited by admin on Sat Jun 26 10:26:38 UTC 2021
NDF-RT N0000175508
Created by admin on Sat Jun 26 10:26:38 UTC 2021 , Edited by admin on Sat Jun 26 10:26:38 UTC 2021
WHO-VATC QJ02AX06
Created by admin on Sat Jun 26 10:26:38 UTC 2021 , Edited by admin on Sat Jun 26 10:26:38 UTC 2021
Code System Code Type Description
MERCK INDEX
M1919
Created by admin on Sat Jun 26 10:26:38 UTC 2021 , Edited by admin on Sat Jun 26 10:26:38 UTC 2021
PRIMARY Merck Index
NCI_THESAURUS
C38716
Created by admin on Sat Jun 26 10:26:38 UTC 2021 , Edited by admin on Sat Jun 26 10:26:38 UTC 2021
PRIMARY
DRUG BANK
DB00362
Created by admin on Sat Jun 26 10:26:38 UTC 2021 , Edited by admin on Sat Jun 26 10:26:38 UTC 2021
PRIMARY
FDA UNII
9HLM53094I
Created by admin on Sat Jun 26 10:26:38 UTC 2021 , Edited by admin on Sat Jun 26 10:26:38 UTC 2021
PRIMARY
DRUG CENTRAL
4357
Created by admin on Sat Jun 26 10:26:38 UTC 2021 , Edited by admin on Sat Jun 26 10:26:38 UTC 2021
PRIMARY
WIKIPEDIA
ANIDULAFUNGIN
Created by admin on Sat Jun 26 10:26:38 UTC 2021 , Edited by admin on Sat Jun 26 10:26:38 UTC 2021
PRIMARY
EVMPD
SUB22240
Created by admin on Sat Jun 26 10:26:38 UTC 2021 , Edited by admin on Sat Jun 26 10:26:38 UTC 2021
PRIMARY
CAS
166663-25-8
Created by admin on Sat Jun 26 10:26:38 UTC 2021 , Edited by admin on Sat Jun 26 10:26:38 UTC 2021
PRIMARY
RXCUI
341018
Created by admin on Sat Jun 26 10:26:38 UTC 2021 , Edited by admin on Sat Jun 26 10:26:38 UTC 2021
PRIMARY RxNorm
ChEMBL
CHEMBL264241
Created by admin on Sat Jun 26 10:26:38 UTC 2021 , Edited by admin on Sat Jun 26 10:26:38 UTC 2021
PRIMARY
INN
7795
Created by admin on Sat Jun 26 10:26:38 UTC 2021 , Edited by admin on Sat Jun 26 10:26:38 UTC 2021
PRIMARY
MESH
C102786
Created by admin on Sat Jun 26 10:26:38 UTC 2021 , Edited by admin on Sat Jun 26 10:26:38 UTC 2021
PRIMARY
PUBCHEM
166548
Created by admin on Sat Jun 26 10:26:38 UTC 2021 , Edited by admin on Sat Jun 26 10:26:38 UTC 2021
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> NON-SUBSTRATE
WAS NOT A SUBSTRATE FOR ANY OTHER CYP ENZYME
METABOLIC ENZYME -> NON-INHIBITOR
DID NOT INHIBIT ANY OTHER CYP ENZYMES
METABOLIC ENZYME -> NON-INDUCER
DID NOT INDUCE ANY OTHER CYP ENZYMES
EXCRETED UNCHANGED
Based on the results of the mass balance study, approximately 10% of the administered dose were excreted in feces and none of the administered dose was excreted in urine.
BINDER->LIGAND
BINDING
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC